Anemia, Iron Deficiency Clinical Trial
Official title:
Intravenous Ferric Derisomaltose For Moderate to Severe Anemia Due To Uterine Bleeding In The Emergency Department: A Randomized Trial
The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.
Iron deficiency anemia (IDA) is the most common hematologic disorder in the United States and worldwide. Patients with moderate to severe anemia often present to the acute care setting for initial assessment and evaluation; women with abnormal uterine bleeding are among those at highest risk. Guidelines on management of this common condition in the emergency department (ED) are lacking. Although IDA is commonly encountered in the ED, there is a paucity of literature addressing optimal management in this setting. Intravenous (IV) iron therapy is infrequently used in the ED despite evidence of safety and superiority to oral iron therapy in other acute care settings. Furthermore, red blood cell (RBC) transfusions may be over-utilized in hemodynamically stable patients with IDA, potentially increasing risk for transfusion reactions, infection, and allo-antibody formation among other adverse outcomes. Improved treatment of iron deficiency may reduce the need for subsequent RBC transfusions. Compared with oral iron, treatment with intravenous iron may result in improved adherence, fewer health care visits, more rapid correction of IDA, and overall improvement in quality of life. Historically, older formulations of IV Iron, namely high-molecular weight iron dextran (HMWID), were associated with unacceptably high rates of severe allergic reactions and/or required multiple doses to replete iron stores. However, newer formulations of IV iron are not only extremely safe, but can also be administered as a single "total dose infusion" over a very short time period. These newer forms of IV iron include ferric carboxymaltose, low-molecular weight iron dextran, ferumoxytol, and ferric derisomaltose. When excluding HMWID, a meta-analysis of 97 RCTs found that there was no increase in the risk of serious adverse events (SAE's) with IV iron compared with control and no increased risk of systemic infection. A large retrospective, "before and after" study conducted in an Italian Emergency Department demonstrated that implementation of Patient Blood Management protocols, including the use of IV iron in the emergency department, resulted in a substantial reduction in red blood cell transfusions, hospitalization, re-transfusion, length of stay and costs. Similar conclusions were reached in smaller studies by Motta et al and Khadadah et al. The investigators recently published a retrospective cohort study examining current emergency department practices in the evaluation and management of IDA in the target population for the proposed trial. The results of this cohort study revealed that women with AUB and severe anemia are frequently seen in the Ben Taub Emergency Department, that red blood cell transfusions are commonly administered, and that IV iron is infrequently (or never) used in the ED setting. Furthermore, unplanned return visits and recurrent transfusions were common. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435574 -
Lactoferrin for Treatment of Iron Deficiency Anemia.
|
Phase 4 | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Not yet recruiting |
NCT05050851 -
Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
|
||
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04626414 -
Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT05047211 -
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
|
Phase 4 | |
Not yet recruiting |
NCT06061393 -
Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia
|
Phase 4 | |
Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
Completed |
NCT03318055 -
Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients
|
||
Completed |
NCT04631679 -
Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
|
||
Recruiting |
NCT05225545 -
Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis
|
Phase 3 | |
Recruiting |
NCT03347513 -
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?
|
Phase 4 | |
Recruiting |
NCT04708665 -
Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
|
||
Completed |
NCT02404012 -
Iron Supplement to Improve Iron Status Following Bariatric Surgery
|
N/A | |
Completed |
NCT04137354 -
Iron and Vitamin A in School Children
|
N/A | |
Not yet recruiting |
NCT06096103 -
A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia
|
N/A | |
Completed |
NCT03156712 -
Iron Absorption From Iron-enriched Aspergillus Oryzae
|
N/A | |
Completed |
NCT05522790 -
Impact of Iron Infusion in Anemic Patients on Their Postoperative Outcome After Colorectal Surgery
|